Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Attention Deficit Disorder With Hyperactivity · Hidradenitis suppurativa (HS) · AVTX

Avalo Therapeutics

Avalo Therapeutics clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US HQ
2011 Founded
48 Employees
Public company Type
AVTX · NYSE Ticker
Company details
Status
Public
HQ
1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
Founded
2011
Employees
48
Programs
17
Drugs
2
Patents
10
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Avalo Therapeutics projects

17 ClinicalTrials.gov programs sponsored by Avalo Therapeutics.

Avalo Therapeutics has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

17 programs

Clinical programs

  1. NFC-1

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  2. AEVI-001

    Avalo Therapeutics

    Attention Deficit Hyperactivity Disorder

    phase 2 small molecule completed

    2 trials

  3. AVTX-002

    Avalo Therapeutics

    Non-Eosinophilic Asthma

    phase 2 small molecule completed

    1 trial

  4. AVTX-009 Regimen 1

    Avalo Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  5. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial

  6. CERC-301

    Avalo Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    2 trials

  7. FP01

    Avalo Therapeutics

    Acute Cough

    phase 2 small molecule completed

    1 trial

  8. FP01

    Avalo Therapeutics

    Chronic Refractory Cough

    phase 2 small molecule completed

    1 trial

  9. MDGN201 TARGTEPO

    Avalo Therapeutics

    Anemia of End Stage Renal Disease

    phase 2 mab terminated

    1 trial

  10. Placebo to AVTX-009, AVTX-009

    Avalo Therapeutics

    Hidradenitis suppurativa (HS)

    phase 2 small molecule active

    1 trial

  11. AEVI-007

    Avalo Therapeutics

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  12. CERC-006

    Avalo Therapeutics

    Lymphatic Malformation

    phase 1 small molecule terminated

    1 trial

  13. FP01

    Avalo Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  14. MDGN-002

    Avalo Therapeutics

    Crohn Disease

    phase 1 small molecule terminated

    1 trial

  15. NFC-1

    Avalo Therapeutics

    Attention-deficit Hyperactivity Disorder (ADHD)

    phase 1 small molecule completed

    1 trial

  16. NFC-1

    Avalo Therapeutics

    22q11.2 Deletion Syndrome

    phase 1 small molecule completed

    1 trial

  17. NFC-1 100 mg

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Avalo Therapeutics have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.